Skip to content

Prognostic Value of Elevated Troponins in Critical Illness Study: A Pilot Study

Prognostic Value of Elevated Troponins in Critical Illness Study: A Pilot Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02285686
Acronym
PRO-TROPICS
Enrollment
251
Registered
2014-11-07
Start date
2014-11-30
Completion date
2015-03-30
Last updated
2017-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Care, Myocardial Infarction, Troponin

Keywords

troponin, biomarkers, myocardial infarction, critical illness

Brief summary

Troponins are sensitive and specific markers of cardiac injury. Critically ill patients frequently have elevated troponins. In this population, distinguishing patients with elevated troponins from those with myocardial infarction is difficult. However, troponin elevations on their own seem to be associated with an increased risk of death. The optimal treatment of patients with type 2 myocardial infarction or non ischemia related troponin elevations during critical illness is unclear. There are no trials in the ICU setting to guide management. This study is a 1-month pilot cohort study of troponin screening in 4 Ontario intensive care units. The objective of this pilot study is to evaluate the ability to perform a larger study, which will determine the prevalence, incidence and risk factors for elevated troponin values, how patients with elevated troponin values are treated as a baseline, and the incidence of myocardial infarction in critically ill patients. Knowing the prognostic impact of these conditions and understanding current management will thereafter guide researchers and clinicians on the importance of carefully evaluating potential risk-modifying therapies.

Interventions

None listed

Sponsors

McMaster University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All adult patients admitted to the participating ICUs of study sites during the study enrollment period will be eligible.

Exclusion criteria

* Patients who are admitted and die or are discharged within 12 hours * Patients re-admitted to ICU during the index ICU enrolment month

Design outcomes

Primary

MeasureTime frameDescription
Recruitment rate1 monthFeasibility outcome
Data collection time per patient3 monthsFeasibility outcome
rate of successful deferred informed consent definition1 monthFeasibility outcome

Secondary

MeasureTime frame
All-cause in-hospital mortality3 months
Troponin elevations3 months
Myocardial infarction3 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026